A Phase Ib Safety Run-In And Randomized Phase II, Open-Label Study To Evaluate The Efficacy, Safety, Tolerability, And Pharmacokinetics Of M6620 In Combination With Avelumab And Carboplatin In Comparison To Standard Of Care Therapy In Participants With Parpi-Resistant Recurrent Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer Read more
A Randomized Phase II Trial Of Radiation Therapy And Cisplatin Alone Or In Combination With Intravenous Triapine In Women With Actively Diagnosed Bulky Stage IB2, Stage II, IIIB, Or IVA Cancer Of The Uterine Cervix Or Stage II-IVA Vaginal Cancer Read more
Phase III Randomized Study Of Concurrent Chemotherapy And Pelvic Radiation Therapy With Or Without Adjuvant Chemotherapy In High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy Read more
A Phase 2, Randomized, Open-Label Three-Arm Clinical Study To Evaluate The Safety And Efficacy Of Lenvatinib (E7080/MK-7902) In Combination With Pembrolizumab (MK-3475) Versus Standard Of Care Chemotherapy And Lenvatinib Monotherapy In Participants With Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy And Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009) Read more
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study Of Pembrolizumab (MK-3475) With Or Without Lenvatinib (E7080/MK-7902) To Evaluate The Safety And Efficacy Of Pembrolizumab And Lenvatinib As 1L Intervention In A PD-L1 Selected Population Of Participants With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) Read more
Observational Study Of Fostamatinib As Second Line Therapy In Adult Patients With Immune Thrombocytopenia (ITP) And Insufficient Response To A Prior Therapy Read more
Phase III Randomized Study Of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy And Consolidation Therapy In Actively Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia Read more
An Open-Label, Randomized Phase 3 Study Of MK-6482 Versus Everolimus In Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 And VEGF-Targeted Therapies Read more
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Of Infigratinib For The Adjuvant Treatment Of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302) Read more
